Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation – Clinical and safety results

This publication has 41 references indexed in Scilit:

• Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review
  Psychiatric Quarterly, 2020
• A New Rapid-Acting Antidepressant
  Cell, 2020
• A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
  JAMA Psychiatry, 2017
• Use of Ketamine in Clinical Practice
  JAMA Psychiatry, 2017
• Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression
  JAMA Psychiatry, 2017
• Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression
  Biological Psychiatry, 2015
• Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5‐year study of 51 patients
  European journal of pain, 2014
• Ketamine administration in depressive disorders: a systematic review and meta-analysis
  Psychopharmacology, 2014
• A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
  Archives of General Psychiatry, 2006
• Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans
  Journal of Pharmaceutical Sciences, 1982